Get to Know Family Offices and Angels at RESI Philadelphia

9 May

By Lucy Parkinson, VP of Investor Research, LSN

Ever since Life Science Nation (LSN) first launched the Redefining Early Stage Investments Conference Series (RESI), we focused on bringing investors from beyond venture capital to meet face to face with entrepreneurs.  Angels and family offices are two of these alternative sources of early stage capital. These investor types are distinct from each other in many ways, and at RESI Philadelphia, the Angels & Family Offices panel will introduce RESI’s entrepreneurs to these distinctions and also the ways in which these private capital pools are working together to fund healthcare innovation.

This discussion will be led by Chuck Stetson (CEO, Stetson Family Office), and the panelists are:

  • Loretta McCarthy (Managing Partner, Golden Seeds)
  • Deanna Belsky (Associate, Dolby Family Ventures)
  • Yaniv Sneor (Founding Member, Mid Atlantic Bio Angels)
  • Richard Anders (Managing Director, Mass Medical Angels)

Chuck Stetson, CEO, Stetson Family Office

Eugene W. Stetson started the Stetson Family Office shortly after he personally led the buyout of The Coca-Cola Company through a public offering in August 1919 by the Guaranty Trust Company of New York, where he subsequently served as Chairman and just before he died and organized, he organize with the much smaller J.P. Morgan. At his death, Eugene was Coca-Cola’s longest serving member of the Board and of the Executive Committee. Chuck Stetson, the third generation running the family office, is an entrepreneur, venture capitalist, and philanthropist. The Stetson Family Office started Healthcare Impact Foundation, a 501-c-3 organization, in 2017 to bring capital and management expertise to local life science companies and to build and maintain an efficient life science eco-system composed of R&D facilities, incubation facilities, venture capital investors, angel investors, family office investors, and networks of experts in science, management, industry, reimbursement and public policy. Stetson Family Office has set up a unique Global Family Office BioForum with family offices around the globe working closely with their local healthcare innovation. Family Offices are responding with excitement.

Loretta McCarthy, Managing Partner, Golden Seeds

Loretta McCarthy is a Managing Partner and Founding Member of Golden Seeds, an investment organization that invests in early-stage, women-led companies in the United States.  Golden Seeds is one of the largest and most active angel investment networks in the country.  It was founded nearly 15 years ago and is recognized for its advocacy of women entrepreneurs, gender diversity and a commitment to education.   Since 2005, Golden Seeds has had over 800 investors who have  invested nearly $120 million in over 150 companies.   Loretta manages the national Golden Seeds angel network.  Previously, she was on Wall Street for over 20 years, at both American Express and OppenheimerFunds.

Deanna Belsky, Associate, Dolby Family Ventures

Deanna currently works at Dolby Family Ventures as an Associate where she is responsible for diligence efforts and portfolio management across the life sciences sector with a focus on neuroscience. Dolby Family Ventures invests in accelerating the path to a cure for Alzheimer’s disease. The portfolio includes novel disease-modifying therapeutics, diagnostics, and technologies that facilitate better science in clinical trials and basic research.

Prior to joining the Dolby Family Ventures team, Deanna worked at both a biotech hedge fund and a life sciences consulting firm where she conducted scientific, clinical, and commercial diligence around novel therapeutics. Before that, she served as a postdoctoral fellow at Stanford University where she studied molecular mechanisms of neurodegeneration. Deanna received her PhD from Rockefeller University studying underlying cell death mechanisms in a mouse model of ALS. She received her BS in Biochemistry and BA in Asian Studies from Indiana University of Pennsylvania.

Yaniv Sneor, Founding Member, Mid Atlantic Bio Angels

Yaniv Sneor is a (reformed) physicist, who made the transition into the business world after being bitten by the entrepreneurial bug.

Yaniv has been involved in founding, growing, managing and re-engineering companies for the past 25+ years, in multiple industries. He ran companies of different sizes and at different life-stages, led re-structuring activities, purchased and sold multiple companies, and negotiated and integrated joint ventures and strategic relationships.

Yaniv is one of the founders of MABA – Mid Atlantic Bio Angels (bioangels.net) a life science angel investor group.  He is president of Blue Cactus Consulting (bluecactusconsulting.com), and CEO of Native State Therapeutics, a recently-formed biotechnology company, in the neurodegenerative space.

Richard Anders, Managing Director, Mass Medical Angels

Richard Anders is is an investor and long-time entrepreneur. He founded the legal software publishing company Jurisoft, which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital Industry and currently serves as managing director of Rubin/Anders Scientific, which places scientists as consultants in patent projects. He has invested in approximately two dozen early-stage startups.

Richard is a long-time trustee of the Museum of Science in Boston, where he is a member of the food committee, exploring science education around the issues of food and its preparation, a trustee of the Forsyth Institute and an overseer at the Brigham & Women’s Hospital and the Gardner Museum. Richard founded and currently runs MA Medical Angels (MA2), one of the country’s leading angel groups focused exclusively on life sciences. He has founded the angel group Launchpad, the nationally renowned Science on Screen event at the Coolidge Corner Cinema and was a founding trustee of the Massachusetts Interactive Media Council. He served for many years as a member of the Dana Farber Cancer Center Institutional Review Board. He is a board observer at Avaxia Biologics and Siamab. Richard teaches medical device entrepreneurship at the Harvard/MIT HST program. He is a graduate Summa Cum Laude in Mathematics from Harvard and holds a J.D. from Harvard Law School.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: